November 6, 2019
Boston-based PathAI, maker of artificial intelligence tools for pathology, has capped off its Series B funding round with a $15 million strategic investment from the Merck Global Health Innovation Fund and Bristol-Myers Squibb. This raise brings the startup’s full round to $75 million, and its total funding to just over $90 million.
WHAT THEY DO
PathAI’s platform employs convolutional neural...
April 18, 2019
Yesterday PathAI, a Boston-based maker of artificial intelligence tools for pathology, closed a $60 million Series B funding round led by General Atlantic. Other existing investors, most notably General Catalyst, also participated in the round.
To monitor its investment, General Atlantic Managing Director Dr. Michelle Dipp will also be joining the AI company’s board of directors.
WHAT THEY DO...
April 8, 2019
Deep Lens, a digital pathology startup particularly focused on cancer trials, has brought in a $13.65 million Series A round, according to an SEC filing. The fundraise was headed by Northpond Ventures with additional support from prior investors Rev1 Ventures, Sierra Ventures and Tamarind-Hill Partners, according to a release.
The Series A comes quickly after a seed funding round that raised just...
October 15, 2018
Columbus, Ohio-based Deep Lens, a digital pathology startup out of Nationwide Children’s Hospital focused on cancer clinical trials, has raised $3.2 million in seed funding. Sierra Ventures led the round with participation from Rev1 Ventures and Tamarin Hill Fund.
With digital pathology, rather than examining a bio specimen with a microscope, a pathologist can study a large number of digitized...